ACTA1 and Hepatic fibrosis: Neat1 simultaneously targeted miR-148a-3p and miR-22-3p, and showed the most significant increase in liver fibrosis mice that displayed the most marked increase in expression upregulation, and its expression in the CCl4 group exceeded 2-fold that of the control group (Huang et al., 2021), and inhibition of NEAT1 was observed to reverse isotropic liver fibrosis with concomitant reduction in α-SMA and type I collagen content, which was further confirmed by NEAT1 knockdown assays and NEAT1 overexpression assays (Yu et al., 2017b).